Literature DB >> 16082328

Impact of statin treatment on 1-year functional and histologic renal allograft outcome.

Rosemary Masterson1, Tim Hewitson, Murray Leikis, Rowan Walker, Shlomo Cohney, Gavin Becker.   

Abstract

BACKGROUND: Statins are antilipidemic agents that exhibit a variety of cellular effects independent of their lipid-lowering action. A retrospective study was undertaken to establish the impact of statins on graft outcome in the first year posttransplantation.
METHODS: Data from patients with uniform immunosuppression (cyclosporine, mycophenolate mofetil, and prednisolone) who underwent transplantation at the authors' unit from 1997 to 2002 were reviewed. Patients prescribed statins were compared with those not on a statin. Mean change in creatinine clearance (CrCl) from 3 to 12 months posttransplantation was calculated. Histomorphometric analysis was used to quantify fractional interstitial area and collagen III deposition in matched preperfusion and 12-month protocol biopsy specimens.
RESULTS: Seventy-seven patients met study criteria: statin, n=44 patients; nonstatin, n=33 patients. Median time to commencing a statin was 5 weeks. At 3 months, CrCl (+/-SEM) was similar: 51.6+/-2.9 mL/min (statin) versus 51.3+/-1 mL/min (nonstatin). At 12 months, the mean change in CrCl was 4.1+/-1 mL/min (statin) compared with -2.0+/-1.8 mL/min (nonstatin), resulting in a difference of 6.13 mL/min at 12 months (P<0.005). Mean preperfusion fractional interstitial areas were similar (23.9+/-1.6%; P=not significant [NS]). On 12-month biopsy specimens, the fractional interstitial area had increased to 34+/-3.2% in the nonstatin group (P<0.005), with no change in the statin group. Interstitial collagen III deposition was similar in preperfusion biopsy specimens (10.4+/-1%; P=NS), but at 12 months it was significantly greater in the nonstatin group (17.6+/-1%; P<0.05)
CONCLUSIONS: Early introduction of statins may be associated with improved 1-year graft outcome.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16082328     DOI: 10.1097/01.tp.0000168941.19689.cf

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  5 in total

1.  Amelioration of human allograft arterial injury by atorvastatin or simvastatin correlates with reduction of interferon-gamma production by infiltrating T cells.

Authors:  Tai Yi; Deepak A Rao; Paul C Y Tang; Yinong Wang; Lisa A Cuchara; Alfred L M Bothwell; Christopher M Colangelo; George Tellides; Jordan S Pober; Marc I Lorber
Journal:  Transplantation       Date:  2008-09-15       Impact factor: 4.939

2.  Long-Term Outcomes and Prognostic Factors in Kidney Transplant Recipients with Polycystic Kidney Disease.

Authors:  Gauri Bhutani; Brad C Astor; Didier A Mandelbrot; Lori Mankowski-Gettle; Timothy Ziemlewicz; Shane A Wells; Leah Frater-Rubsam; Vanessa Horner; Courtney Boyer; Jennifer Laffin; Arjang Djamali
Journal:  Kidney360       Date:  2020-12-04

3.  HMG-CoA reductase inhibitors in kidney transplant recipients receiving tacrolimus: statins not associated with improved patient or graft survival.

Authors:  Nizar Younas; Christine M Wu; Ron Shapiro; Jerry McCauley; James Johnston; Henkie Tan; Amit Basu; Heidi Schaefer; Cynthia Smetanka; Wolfgang C Winkelmayer; Mark Unruh
Journal:  BMC Nephrol       Date:  2010-04-01       Impact factor: 2.388

4.  Effect of Statins on the Progression of Coronary Calcification in Kidney Transplant Recipients.

Authors:  Daniel Constantino Yazbek; Aluizio Barbosa de Carvalho; Cinara Sá Barros; Jose Osmar Medina Pestana; Maria Eugênia F Canziani
Journal:  PLoS One       Date:  2016-04-21       Impact factor: 3.240

5.  Effects of Statins on Lipid Profile of Kidney Transplant Recipients: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Xiu Huang; Yong Jia; Xiaoyu Zhu; Yangyang Zhang; Lili Jiang; Xuejiao Wei; Dan Zhao; Xiaoxia Zhao; Yujun Du
Journal:  Biomed Res Int       Date:  2020-05-02       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.